Shanghai Jianxin Capital

Shanghai Jianxin Capital is a venture capital firm specializing in the healthcare industry in China. The firm focuses on investments in the pharmaceutical and health sectors, leveraging a professional biomedical investment team with extensive experience in medical and financial fields. This expertise enables them to make prospective investment layouts aligned with industry development trends, creating value for enterprises and investors.

The firm's investment strategy encompasses various stages, including early-stage, late-stage, and private equity investments. Their portfolio spans multiple sectors within the healthcare industry, such as pharmaceuticals and biotechnology. Shanghai Jianxin Capital's team comprises nearly 20 professionals with backgrounds in medical institutions and financial sectors, both domestically and internationally. This diverse expertise allows them to provide comprehensive value-added services to their portfolio companies, addressing needs in product development, industrialization, management, and financial investment.

Shanghai Jianxin Capital has a track record of active investments, with recent funding rounds in companies like Hegea Bio and Isabers. Their approach combines deep industry knowledge with financial acumen to support the growth and success of healthcare enterprises in China.